Clinicopathological features of Churg–Strauss syndrome-associated neuropathy

We assessed the clinicopathological features of 28 patients with peripheral neuropathy associated with Churg–Strauss syndrome. Initial symptoms attributable to neuropathy were acute painful dysaesthesiae and oedema in the dysaesthetic portion of the distal limbs. Sensory and motor involvement mostly...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brain (London, England : 1878) England : 1878), 1999-03, Vol.122 (3), p.427-439
Hauptverfasser: Hattori, Naoki, Ichimura, Miyuki, Nagamatsu, Masaaki, Li, Mei, Yamamoto, Koji, Kumazawa, Kazuhiko, Mitsuma, Terunori, Sobue, Gen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 439
container_issue 3
container_start_page 427
container_title Brain (London, England : 1878)
container_volume 122
creator Hattori, Naoki
Ichimura, Miyuki
Nagamatsu, Masaaki
Li, Mei
Yamamoto, Koji
Kumazawa, Kazuhiko
Mitsuma, Terunori
Sobue, Gen
description We assessed the clinicopathological features of 28 patients with peripheral neuropathy associated with Churg–Strauss syndrome. Initial symptoms attributable to neuropathy were acute painful dysaesthesiae and oedema in the dysaesthetic portion of the distal limbs. Sensory and motor involvement mostly showed a pattern of mononeuritis multiplex in the initial phase, progressing into asymmetrical polyneuropathy, restricted to the limbs. Parallel loss of myelinated and unmyelinated fibres due to axonal degeneration was evident as decreased or absent amplitudes of sensory nerve action potentials and compound muscle action potentials, indicating acute massive axonal loss. Epineurial necrotizing vasculitis was seen in 54% of cases; infiltrates consisted mainly of CD8-positive suppressor/cytotoxic and CD4-positive helper T lymphocytes. Eosinophils were present in infiltrates, but in smaller numbers than lymphocytes. CD20-positive B lymphocytes were seen only occasionally. Deposits of IgG, C3d, IgE and major basic protein were scarce. The mean follow-up period was 4.2 years, with a range of 8 months to 10 years. Fatal outcome was seen only in a single patient, indicating a good survival rate. The patients who responded well to the initial corticosteroid therapy within 4 weeks regained self-controlled functional status in long-term follow-up (modified Rankin score was ≤2), while those not responding well to the initial corticosteroid therapy led a dependent existence (P < 0.01). In addition the patients with poor functional outcomes had significantly more systemic organ damage caused by vasculitis (P < 0.05). Necrotizing vasculitis mediated by cytotoxic T cells, leading to ischaemic changes, appears to be a major cause of Churg–Strauss syndrome-associated neuropathy. The initial clinical course and the extent of systemic vasculitic lesions may influence the long-term functional prognosis.
doi_str_mv 10.1093/brain/122.3.427
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69648438</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>39905784</sourcerecordid><originalsourceid>FETCH-LOGICAL-c525t-7b1536252d3fb67887a55b77e0bcd0687d683d9adf27b178266acc96e79b14b3</originalsourceid><addsrcrecordid>eNqF0U9rFDEYBvAgil2rZ28yiPQ2u2_-J0dZtFtYrGJB8RIymUybOjvZJjPg3vwOfkM_SdPuosWLpxzyy8Ob90HoJYY5Bk0XTbJhWGBC5nTOiHyEZpgJqAnm4jGaAYColeZwhJ7lfA2AGSXiKTrCAJoRTmbow7IPQ3Bxa8er2MfL4Gxfdd6OU_K5il21vJrS5e-fvz6PyU45V3k3tClufG1zji7Y0bfV4Kd0n7B7jp50ts_-xeE8Rhfv310sV_X6_PRs-XZdO074WMsGcyrKAC3tGiGVkpbzRkoPjWtBKNkKRVtt244UKhURwjqnhZe6wayhx-hkH7tN8WbyeTSbkJ3vezv4OGUjtGCKUfVfSEBgppko8PU_8DpOaSh_MFhzRoWCO7TYI5dizsl3ZpvCxqadwWDu-jD3fZjSh6Gm9FFevDrETs3Gtw_8voAC3hyAzWX1XbKDC_mvk0AAWGH1noU8-h9_rm36boSkkpvV12-Grhhdf_kkzUd6CyHjo9g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>195436806</pqid></control><display><type>article</type><title>Clinicopathological features of Churg–Strauss syndrome-associated neuropathy</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Hattori, Naoki ; Ichimura, Miyuki ; Nagamatsu, Masaaki ; Li, Mei ; Yamamoto, Koji ; Kumazawa, Kazuhiko ; Mitsuma, Terunori ; Sobue, Gen</creator><creatorcontrib>Hattori, Naoki ; Ichimura, Miyuki ; Nagamatsu, Masaaki ; Li, Mei ; Yamamoto, Koji ; Kumazawa, Kazuhiko ; Mitsuma, Terunori ; Sobue, Gen</creatorcontrib><description>We assessed the clinicopathological features of 28 patients with peripheral neuropathy associated with Churg–Strauss syndrome. Initial symptoms attributable to neuropathy were acute painful dysaesthesiae and oedema in the dysaesthetic portion of the distal limbs. Sensory and motor involvement mostly showed a pattern of mononeuritis multiplex in the initial phase, progressing into asymmetrical polyneuropathy, restricted to the limbs. Parallel loss of myelinated and unmyelinated fibres due to axonal degeneration was evident as decreased or absent amplitudes of sensory nerve action potentials and compound muscle action potentials, indicating acute massive axonal loss. Epineurial necrotizing vasculitis was seen in 54% of cases; infiltrates consisted mainly of CD8-positive suppressor/cytotoxic and CD4-positive helper T lymphocytes. Eosinophils were present in infiltrates, but in smaller numbers than lymphocytes. CD20-positive B lymphocytes were seen only occasionally. Deposits of IgG, C3d, IgE and major basic protein were scarce. The mean follow-up period was 4.2 years, with a range of 8 months to 10 years. Fatal outcome was seen only in a single patient, indicating a good survival rate. The patients who responded well to the initial corticosteroid therapy within 4 weeks regained self-controlled functional status in long-term follow-up (modified Rankin score was ≤2), while those not responding well to the initial corticosteroid therapy led a dependent existence (P &lt; 0.01). In addition the patients with poor functional outcomes had significantly more systemic organ damage caused by vasculitis (P &lt; 0.05). Necrotizing vasculitis mediated by cytotoxic T cells, leading to ischaemic changes, appears to be a major cause of Churg–Strauss syndrome-associated neuropathy. The initial clinical course and the extent of systemic vasculitic lesions may influence the long-term functional prognosis.</description><identifier>ISSN: 0006-8950</identifier><identifier>EISSN: 1460-2156</identifier><identifier>DOI: 10.1093/brain/122.3.427</identifier><identifier>PMID: 10094252</identifier><identifier>CODEN: BRAIAK</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Aged ; Anti-Inflammatory Agents - therapeutic use ; Asthma - drug therapy ; Asthma - physiopathology ; Biological and medical sciences ; Blood and lymphatic vessels ; Blood Cell Count ; Cardiology. Vascular system ; Churg-Strauss Syndrome - complications ; Churg-Strauss Syndrome - drug therapy ; Churg-Strauss Syndrome - pathology ; Churg-Strauss Syndrome - physiopathology ; Churg–Strauss syndrome ; CMAP = compound muscle action potential ; corticosteroids ; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous ; ESR = erythrocyte sedimentation rate ; Female ; Follow-Up Studies ; Humans ; LDH = lactate dehydrogenase ; Male ; Medical sciences ; Middle Aged ; p-ANCA = perinuclear antineutrophil cytoplasmic antibody ; PAN = polyarteritis nodosa ; Peripheral Nervous System Diseases - drug therapy ; Peripheral Nervous System Diseases - etiology ; Peripheral Nervous System Diseases - pathology ; Peripheral Nervous System Diseases - physiopathology ; Prognosis ; RA = rheumatoid arthritis ; SNAP = sensory nerve action potential ; SNVDI = systemic necrotizing vasculitis damage index ; Steroids ; Sural Nerve - pathology ; T-cell infiltration ; Treatment Outcome ; vasculitic neuropathy</subject><ispartof>Brain (London, England : 1878), 1999-03, Vol.122 (3), p.427-439</ispartof><rights>1999 INIST-CNRS</rights><rights>Copyright Oxford University Press Mar 1999</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c525t-7b1536252d3fb67887a55b77e0bcd0687d683d9adf27b178266acc96e79b14b3</citedby><cites>FETCH-LOGICAL-c525t-7b1536252d3fb67887a55b77e0bcd0687d683d9adf27b178266acc96e79b14b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1702004$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10094252$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hattori, Naoki</creatorcontrib><creatorcontrib>Ichimura, Miyuki</creatorcontrib><creatorcontrib>Nagamatsu, Masaaki</creatorcontrib><creatorcontrib>Li, Mei</creatorcontrib><creatorcontrib>Yamamoto, Koji</creatorcontrib><creatorcontrib>Kumazawa, Kazuhiko</creatorcontrib><creatorcontrib>Mitsuma, Terunori</creatorcontrib><creatorcontrib>Sobue, Gen</creatorcontrib><title>Clinicopathological features of Churg–Strauss syndrome-associated neuropathy</title><title>Brain (London, England : 1878)</title><addtitle>Brain</addtitle><description>We assessed the clinicopathological features of 28 patients with peripheral neuropathy associated with Churg–Strauss syndrome. Initial symptoms attributable to neuropathy were acute painful dysaesthesiae and oedema in the dysaesthetic portion of the distal limbs. Sensory and motor involvement mostly showed a pattern of mononeuritis multiplex in the initial phase, progressing into asymmetrical polyneuropathy, restricted to the limbs. Parallel loss of myelinated and unmyelinated fibres due to axonal degeneration was evident as decreased or absent amplitudes of sensory nerve action potentials and compound muscle action potentials, indicating acute massive axonal loss. Epineurial necrotizing vasculitis was seen in 54% of cases; infiltrates consisted mainly of CD8-positive suppressor/cytotoxic and CD4-positive helper T lymphocytes. Eosinophils were present in infiltrates, but in smaller numbers than lymphocytes. CD20-positive B lymphocytes were seen only occasionally. Deposits of IgG, C3d, IgE and major basic protein were scarce. The mean follow-up period was 4.2 years, with a range of 8 months to 10 years. Fatal outcome was seen only in a single patient, indicating a good survival rate. The patients who responded well to the initial corticosteroid therapy within 4 weeks regained self-controlled functional status in long-term follow-up (modified Rankin score was ≤2), while those not responding well to the initial corticosteroid therapy led a dependent existence (P &lt; 0.01). In addition the patients with poor functional outcomes had significantly more systemic organ damage caused by vasculitis (P &lt; 0.05). Necrotizing vasculitis mediated by cytotoxic T cells, leading to ischaemic changes, appears to be a major cause of Churg–Strauss syndrome-associated neuropathy. The initial clinical course and the extent of systemic vasculitic lesions may influence the long-term functional prognosis.</description><subject>Adult</subject><subject>Aged</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Asthma - drug therapy</subject><subject>Asthma - physiopathology</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Blood Cell Count</subject><subject>Cardiology. Vascular system</subject><subject>Churg-Strauss Syndrome - complications</subject><subject>Churg-Strauss Syndrome - drug therapy</subject><subject>Churg-Strauss Syndrome - pathology</subject><subject>Churg-Strauss Syndrome - physiopathology</subject><subject>Churg–Strauss syndrome</subject><subject>CMAP = compound muscle action potential</subject><subject>corticosteroids</subject><subject>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</subject><subject>ESR = erythrocyte sedimentation rate</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>LDH = lactate dehydrogenase</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>p-ANCA = perinuclear antineutrophil cytoplasmic antibody</subject><subject>PAN = polyarteritis nodosa</subject><subject>Peripheral Nervous System Diseases - drug therapy</subject><subject>Peripheral Nervous System Diseases - etiology</subject><subject>Peripheral Nervous System Diseases - pathology</subject><subject>Peripheral Nervous System Diseases - physiopathology</subject><subject>Prognosis</subject><subject>RA = rheumatoid arthritis</subject><subject>SNAP = sensory nerve action potential</subject><subject>SNVDI = systemic necrotizing vasculitis damage index</subject><subject>Steroids</subject><subject>Sural Nerve - pathology</subject><subject>T-cell infiltration</subject><subject>Treatment Outcome</subject><subject>vasculitic neuropathy</subject><issn>0006-8950</issn><issn>1460-2156</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0U9rFDEYBvAgil2rZ28yiPQ2u2_-J0dZtFtYrGJB8RIymUybOjvZJjPg3vwOfkM_SdPuosWLpxzyy8Ob90HoJYY5Bk0XTbJhWGBC5nTOiHyEZpgJqAnm4jGaAYColeZwhJ7lfA2AGSXiKTrCAJoRTmbow7IPQ3Bxa8er2MfL4Gxfdd6OU_K5il21vJrS5e-fvz6PyU45V3k3tClufG1zji7Y0bfV4Kd0n7B7jp50ts_-xeE8Rhfv310sV_X6_PRs-XZdO074WMsGcyrKAC3tGiGVkpbzRkoPjWtBKNkKRVtt244UKhURwjqnhZe6wayhx-hkH7tN8WbyeTSbkJ3vezv4OGUjtGCKUfVfSEBgppko8PU_8DpOaSh_MFhzRoWCO7TYI5dizsl3ZpvCxqadwWDu-jD3fZjSh6Gm9FFevDrETs3Gtw_8voAC3hyAzWX1XbKDC_mvk0AAWGH1noU8-h9_rm36boSkkpvV12-Grhhdf_kkzUd6CyHjo9g</recordid><startdate>19990301</startdate><enddate>19990301</enddate><creator>Hattori, Naoki</creator><creator>Ichimura, Miyuki</creator><creator>Nagamatsu, Masaaki</creator><creator>Li, Mei</creator><creator>Yamamoto, Koji</creator><creator>Kumazawa, Kazuhiko</creator><creator>Mitsuma, Terunori</creator><creator>Sobue, Gen</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>19990301</creationdate><title>Clinicopathological features of Churg–Strauss syndrome-associated neuropathy</title><author>Hattori, Naoki ; Ichimura, Miyuki ; Nagamatsu, Masaaki ; Li, Mei ; Yamamoto, Koji ; Kumazawa, Kazuhiko ; Mitsuma, Terunori ; Sobue, Gen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c525t-7b1536252d3fb67887a55b77e0bcd0687d683d9adf27b178266acc96e79b14b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Asthma - drug therapy</topic><topic>Asthma - physiopathology</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Blood Cell Count</topic><topic>Cardiology. Vascular system</topic><topic>Churg-Strauss Syndrome - complications</topic><topic>Churg-Strauss Syndrome - drug therapy</topic><topic>Churg-Strauss Syndrome - pathology</topic><topic>Churg-Strauss Syndrome - physiopathology</topic><topic>Churg–Strauss syndrome</topic><topic>CMAP = compound muscle action potential</topic><topic>corticosteroids</topic><topic>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</topic><topic>ESR = erythrocyte sedimentation rate</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>LDH = lactate dehydrogenase</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>p-ANCA = perinuclear antineutrophil cytoplasmic antibody</topic><topic>PAN = polyarteritis nodosa</topic><topic>Peripheral Nervous System Diseases - drug therapy</topic><topic>Peripheral Nervous System Diseases - etiology</topic><topic>Peripheral Nervous System Diseases - pathology</topic><topic>Peripheral Nervous System Diseases - physiopathology</topic><topic>Prognosis</topic><topic>RA = rheumatoid arthritis</topic><topic>SNAP = sensory nerve action potential</topic><topic>SNVDI = systemic necrotizing vasculitis damage index</topic><topic>Steroids</topic><topic>Sural Nerve - pathology</topic><topic>T-cell infiltration</topic><topic>Treatment Outcome</topic><topic>vasculitic neuropathy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hattori, Naoki</creatorcontrib><creatorcontrib>Ichimura, Miyuki</creatorcontrib><creatorcontrib>Nagamatsu, Masaaki</creatorcontrib><creatorcontrib>Li, Mei</creatorcontrib><creatorcontrib>Yamamoto, Koji</creatorcontrib><creatorcontrib>Kumazawa, Kazuhiko</creatorcontrib><creatorcontrib>Mitsuma, Terunori</creatorcontrib><creatorcontrib>Sobue, Gen</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Brain (London, England : 1878)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hattori, Naoki</au><au>Ichimura, Miyuki</au><au>Nagamatsu, Masaaki</au><au>Li, Mei</au><au>Yamamoto, Koji</au><au>Kumazawa, Kazuhiko</au><au>Mitsuma, Terunori</au><au>Sobue, Gen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinicopathological features of Churg–Strauss syndrome-associated neuropathy</atitle><jtitle>Brain (London, England : 1878)</jtitle><addtitle>Brain</addtitle><date>1999-03-01</date><risdate>1999</risdate><volume>122</volume><issue>3</issue><spage>427</spage><epage>439</epage><pages>427-439</pages><issn>0006-8950</issn><eissn>1460-2156</eissn><coden>BRAIAK</coden><abstract>We assessed the clinicopathological features of 28 patients with peripheral neuropathy associated with Churg–Strauss syndrome. Initial symptoms attributable to neuropathy were acute painful dysaesthesiae and oedema in the dysaesthetic portion of the distal limbs. Sensory and motor involvement mostly showed a pattern of mononeuritis multiplex in the initial phase, progressing into asymmetrical polyneuropathy, restricted to the limbs. Parallel loss of myelinated and unmyelinated fibres due to axonal degeneration was evident as decreased or absent amplitudes of sensory nerve action potentials and compound muscle action potentials, indicating acute massive axonal loss. Epineurial necrotizing vasculitis was seen in 54% of cases; infiltrates consisted mainly of CD8-positive suppressor/cytotoxic and CD4-positive helper T lymphocytes. Eosinophils were present in infiltrates, but in smaller numbers than lymphocytes. CD20-positive B lymphocytes were seen only occasionally. Deposits of IgG, C3d, IgE and major basic protein were scarce. The mean follow-up period was 4.2 years, with a range of 8 months to 10 years. Fatal outcome was seen only in a single patient, indicating a good survival rate. The patients who responded well to the initial corticosteroid therapy within 4 weeks regained self-controlled functional status in long-term follow-up (modified Rankin score was ≤2), while those not responding well to the initial corticosteroid therapy led a dependent existence (P &lt; 0.01). In addition the patients with poor functional outcomes had significantly more systemic organ damage caused by vasculitis (P &lt; 0.05). Necrotizing vasculitis mediated by cytotoxic T cells, leading to ischaemic changes, appears to be a major cause of Churg–Strauss syndrome-associated neuropathy. The initial clinical course and the extent of systemic vasculitic lesions may influence the long-term functional prognosis.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>10094252</pmid><doi>10.1093/brain/122.3.427</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-8950
ispartof Brain (London, England : 1878), 1999-03, Vol.122 (3), p.427-439
issn 0006-8950
1460-2156
language eng
recordid cdi_proquest_miscellaneous_69648438
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Adult
Aged
Anti-Inflammatory Agents - therapeutic use
Asthma - drug therapy
Asthma - physiopathology
Biological and medical sciences
Blood and lymphatic vessels
Blood Cell Count
Cardiology. Vascular system
Churg-Strauss Syndrome - complications
Churg-Strauss Syndrome - drug therapy
Churg-Strauss Syndrome - pathology
Churg-Strauss Syndrome - physiopathology
Churg–Strauss syndrome
CMAP = compound muscle action potential
corticosteroids
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
ESR = erythrocyte sedimentation rate
Female
Follow-Up Studies
Humans
LDH = lactate dehydrogenase
Male
Medical sciences
Middle Aged
p-ANCA = perinuclear antineutrophil cytoplasmic antibody
PAN = polyarteritis nodosa
Peripheral Nervous System Diseases - drug therapy
Peripheral Nervous System Diseases - etiology
Peripheral Nervous System Diseases - pathology
Peripheral Nervous System Diseases - physiopathology
Prognosis
RA = rheumatoid arthritis
SNAP = sensory nerve action potential
SNVDI = systemic necrotizing vasculitis damage index
Steroids
Sural Nerve - pathology
T-cell infiltration
Treatment Outcome
vasculitic neuropathy
title Clinicopathological features of Churg–Strauss syndrome-associated neuropathy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T21%3A01%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinicopathological%20features%20of%20Churg%E2%80%93Strauss%20syndrome-associated%20neuropathy&rft.jtitle=Brain%20(London,%20England%20:%201878)&rft.au=Hattori,%20Naoki&rft.date=1999-03-01&rft.volume=122&rft.issue=3&rft.spage=427&rft.epage=439&rft.pages=427-439&rft.issn=0006-8950&rft.eissn=1460-2156&rft.coden=BRAIAK&rft_id=info:doi/10.1093/brain/122.3.427&rft_dat=%3Cproquest_cross%3E39905784%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=195436806&rft_id=info:pmid/10094252&rfr_iscdi=true